![]() ![]() Below we highlight significant topics of interest in both divisions While we model full-year 2016 revenue to show a 37% decline from the previous year, reflecting 11% and 61% contractions in Detection and Therapy revenue, respectively, we think both segments return to double-digit positive sales growth in 2017. launch of the 3D tomosynthesis product have also trimmed Detection revenue expectations for 2016. Detection revenue has fared much better, but is still down over 13% over the same period and has been hampered by the loss of iCAD’s (ICAD) MRI distribution agreement (as of August 2015). Therapy revenue through the first nine months of the year is down 66%, largely as a result of the unfavorable change to reimbursement of non-melanoma skin cancer. Certain Catalysts Expected to Return ICAD ( ICAD) to Positive Revenue Growth in 20172016 has been a disappointing year in terms of revenue. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |